Allakos Inc


Prices are adjusted according to historical splits.

Allakos Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$558.08 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Allakos Inc had its IPO on 2018-07-19 under the ticker symbol ALLK.

The company operates in the Healthcare sector and Biotechnology industry. Allakos Inc has a staff strength of 192 employees.

Stock update

Shares of Allakos Inc opened at $4.68 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $4.51 - $4.78, and closed at $4.61.

This is a -2.54% slip from the previous day's closing price.

A total volume of 757,314 shares were traded at the close of the day’s session.

In the last one week, shares of Allakos Inc have slipped by -16.18%.

Allakos Inc's Key Ratios

Allakos Inc has a market cap of $558.08 million, indicating a price to book ratio of 1.8517 and a price to sales ratio of 0.

In the last 12-months Allakos Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-315358016. The EBITDA ratio measures Allakos Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Allakos Inc’s operating margin was 0% while its return on assets stood at -43.75% with a return of equity of -84.65%.

In Q4, Allakos Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Allakos Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-6.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Allakos Inc’s profitability.

Allakos Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.9899. Its price to sales ratio in the trailing 12-months stood at 0.

Allakos Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$386.42 million
Total Liabilities
$30.04 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Allakos Inc ended 2023 with $386.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $386.42 million while shareholder equity stood at $310.43 million.

Allakos Inc ended 2023 with $0 in deferred long-term liabilities, $30.04 million in other current liabilities, 85000.00 in common stock, $-932776000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $87.22 million and cash and short-term investments were $279.79 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Allakos Inc’s total current assets stands at $308.84 million while long-term investments were $0 and short-term investments were $192.57 million. Its net receivables were $0 compared to accounts payable of $4.83 million and inventory worth $0.

In 2023, Allakos Inc's operating cash flow was $-71477000.00 while its capital expenditure stood at $291000.

Comparatively, Allakos Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Allakos Inc stock is currently trading at $4.61 per share. It touched a 52-week high of $8.73 and a 52-week low of $8.73. Analysts tracking the stock have a 12-month average target price of $5.44.

Its 50-day moving average was $6.42 and 200-day moving average was $5.65 The short ratio stood at 3.68 indicating a short percent outstanding of 0%.

Around 418.5% of the company’s stock are held by insiders while 9184.7% are held by institutions.

Frequently Asked Questions About Allakos Inc

The stock symbol (also called stock or share ticker) of Allakos Inc is ALLK

The IPO of Allakos Inc took place on 2018-07-19

Similar Industry Stocks (Biotechnology)

Last Price
Unit Corp (UNTC)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.


975 Island Drive, Redwood City, CA, United States, 94065